Search Results
Your search for The matches 34883 pages
Showing 20251 - 20300Cumulative Burden of Chronic Health Conditions in Childhood Cancer Survivors
In a report from the St Jude Lifetime Cohort Study published in The Lancet, Bhakta et al detailed the burden of lifetime chronic health conditions in survivors of childhood cancers. The report included retrospectively collected data on chronic health conditions in 5,522 patients treated for...
MicroRNA-Loaded Minicells in Recurrent Malignant Pleural Mesothelioma
An Australian phase I first-in-human trial has shown early activity of microRNA-loaded minicells in patients with malignant pleural mesothelioma. These findings were reported in The Lancet Oncology by van Zandwijk et al. The minicells (TargomiRs) are loaded with miR-16–based mimic microRNA...
Marcus E. Randall, MD, on Endometrial Cancer: Results From a Gynecology Oncology Group Study
Marcus E. Randall, MD, of the University of Kentucky, discusses phase III study findings on pelvic radiation therapy vs vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early stage endometrial cancer (Abstract LBA1).
Juanita Crook, MD, on Prostate Cancer: Results From an NRG/RTOG Brachytherapy Trial
Juanita Crook, MD, of the University of British Columbia, discusses late toxicity findings on transperineal ultrasound–guided brachytherapy for locally recurrent prostate cancer after external-beam radiation therapy (Abstract 1).
James E. Bates, MD, on Pediatric Cancer Survivors: New Findings on Late Effects
James E. Bates, MD, of the University of Florida, discusses a volumetric dose-effect analysis of late cardiotoxicity, results from the Childhood Cancer Survivor Study (Abstract 4).
ASTRO 2017: Radiation-Immunotherapy Combination May Benefit Some Patients With Late-Stage Cancer
A new study involving patients with stage IV cancer has found that treatment with radiation therapy and immunotherapy can slow tumor growth by stimulating the body’s immune system to attack the cancer. In the phase II trial, patients with end-stage cancer that had metastasized to the lungs or ...
ASTRO 2017: Distress in Patients Receiving Radiation Associated With Missed Appointments, Hospitalization
Psychological distress has long been associated with negative health outcomes for patients with cancer, though specific reasons remain unclear. A new study has found that roughly half of all patients who reported having severe distress, which the National Comprehensive Cancer Network® (NCCN)...
ASTRO 2017: Adding Radiation to Maintenance Chemotherapy May Benefit Patients With Limited Metastatic NSCLC
For patients with limited metastatic non–small cell lung cancer (NSCLC), adding radiation therapy before maintenance chemotherapy may curb disease progression when compared to maintenance chemotherapy alone, according to a randomized phase II clinical trial reported by Iyengar et al. at the...
Addition of Motesanib to Paclitaxel/Carboplatin in East Asian Patients With Advanced NSCLC
The phase III MONET-A trial has shown that the addition of the multikinase/vascular endothelial growth factor receptor inhibitor motesanib to paclitaxel and carboplatin did not significantly improve progression-free survival in East Asian patients with stage IV/recurrent nonsquamous non–small ...
Adjuvant Dabrafenib and Trametinib in Resected Stage III BRAF-Mutated Melanoma
The phase III COMBI-AD trial has shown a significant improvement in relapse-free survival with the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) vs placebo as adjuvant therapy in patients with resected stage III melanoma with BRAF V600E or V600K ...
Study Finds Smoking Negatively Impacts Long-Term Survival After Breast Cancer
According to the American Cancer Society, about 316,120 new cases of breast cancer will be diagnosed this year, and over 40,000 women will die of the disease. Between 10% and 20% of women diagnosed with cancer are current smokers. Now, a prospective study by Parada et al investigating whether...
ASTRO 2017: Biomarker Blood Test Predicts Survival Following Localized Lung Cancer Treatment
A new study demonstrates that a blood test to detect cancer may predict treatment outcomes for patients with localized non–small cell lung cancer (NSCLC) and afford physicians additional lead time to personalize treatment for recurrent disease. Patients in the study with detectable levels of...
ASTRO 2017: IAEA Trial: Safety, Efficacy of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy, or internal radiation therapy, for managing locally advanced cervical cancer. Tumor control was significantly better following four fractions of 7 Gy each than following two 9-Gy...
ASTRO 2017: Urban Cancer Center Finds 75% of Its Patients With Depression Were Previously Undiagnosed
A new study of patients at an urban cancer center points to a potentially serious problem that may limit the impact of clinical cancer care—undiagnosed depression. Among the 40% of patients at the center who were diagnosed with depression, three in four had not previously been told they were ...
FDA Grants Accelerated Approval to Pembrolizumab for Advanced Gastric Cancer
On September 22, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for patients with recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma whose tumors express programmed cell death ligand 1 (PD-L1) as...
FDA Grants Accelerated Approval to Nivolumab for Hepatocellular Carcinoma Previously Treated With Sorafenib
On September 22, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo) for the treatment of hepatocellular carcinoma in patients who have been previously treated with sorafenib (Nexavar). CheckMate 040 Approval was based on a 154-patient subgroup of...
Heart Disease, Cancer, Leading Causes of Death due to Noncommunicable Diseases, Global Study Finds
The Global Burden of Disease Study, published in The Lancet, finds that of noncommunicable diseases, cancer is the second-leading cause of death globally.1 The report also finds that deaths from cancer increased more than 17% between 2006 and 2016. The Global Burden of Disease Study is a...
I Don’t Feel Like I Have Incurable Cancer
A series of medical mishaps has led me to a diagnosis of stage IV carcinoid neuroendocrine cancer and a shortened lifespan. This never should have happened. For months in early 2015, I was plagued with all the signs of a serious illness, including chronic stomach, bowel, and digestive issues;...
Neurocognitive Function in Patients Treated for B-Lineage ALL
In a Children’s Oncology Group (COG) study (AALL06N1) reported in the Journal of Clinical Oncology, Hardy et al found that age < 10 years at diagnosis was associated with poorer neurocognitive function in patients with high-risk B-lineage acute lymphoblastic leukemia (ALL) regardless of...
Adding Midostaurin to Chemotherapy in AML With FLT3 Mutation
In a phase III trial (Cancer and Leukemia Group B 10603 [RATIFY]/Alliance) reported in The New England Journal of Medicine, Stone et al found that the addition of midostaurin (Rydapt) to standard chemotherapy improved overall survival in patients with newly diagnosed acute myeloid leukemia (AML)...
Trastuzumab-Based Regimens in Older Women With Early Breast Cancer
A comparative analysis of outcomes with two different trastuzumab (Herceptin)-based adjuvant regimens in older women with early HER2-positive breast cancer found little difference in safety and efficacy between treatments. The study was reported by Katherine E. Reeder-Hayes, MD, MBA, of the...
Tumor-Infiltrating Lymphocytes in African Americans and European Americans With Triple-Negative Breast Cancer
Triple-negative breast cancer is a highly aggressive breast cancer that lacks hormone receptors and overexpression of human epidermal growth factor receptor 2 (HER2/neu), and, therefore, there are no targeted treatments available for the cancer. Triple-negative breast cancer afflicts African...
ASH Honors Marshall A. Lichtman, MD, With Lifetime Achievement in Hematology Award
The American Society of Hematology (ASH) will recognize Marshall A. Lichtman, MD, of the University of Rochester School of Medicine and Dentistry, with the 2017 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Lichtman will be honored for his notable service to the field of...
The Dark Side of Medicine: Physician Suicide
The statistics on physician suicide are stark: Physicians are more than twice as likely to take their own lives as nonphysicians, and more than 400 physicians commit suicide each year in the United States. Moreover, young physicians at the early part of their training are reported to be...
NCI-COG Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers
Investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) have announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) is a nationwide trial to explore whether...
WISDOM Study to Test Personalized Approach to Breast Cancer Screening
MANY health-care experts disagree about when screening mammography is appropriate and for whom. That’s what Women Informed to Screen Depending on Measures of Risk (WISDOM) seeks to remedy. The University of California (UC) Health study aims to uncover whether annual mammograms really are the best...
ACS Awards Grants to Reduce Colorectal Cancer Disparities in American Indian and Alaska Native Populations
The American Cancer Society (ACS) has awarded $100,000 in grants to five community health centers across the country to reduce colon cancer disparities in American Indian and Alaska Native populations through the Community Health Advocates implementing Nationwide Grants for Empowerment and Equity...
Bringing Oncology Care to Rural Communities
The organizations and programs listed here are helping to address and reduce disparities in cancer care in rural communities. ASCO University Disparities in Cancer Care: Take Action (http://university.asco.org/disparities-cancer-care-take-action). This free slide-based course is designed to help...
Stemming the Growing Cancer Crisis in Rural Appalachia
A pair of recent studies show a troubling trend: Despite a 20% decrease in cancer mortality rates nationwide over the past 2 decades,1 Americans living in rural regions of the United States are more likely to die of cancer than persons living in metropolitan areas of the country. An analysis of...
Rhodiola
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, present information on...
Emotional and Psychological Distress Associated With Prostate Cancer
A cancer diagnosis presents emotional and psychological challenges for patients and caregivers, and prostate cancer has some unique challenges, in part because management is not writ in stone. At several points along the trajectory of illness, men with prostate cancer face decisions that can be...
Preexisting Dementia and Survival in Older Patients With Stage III Colon Cancer
A pre-existing diagnosis of dementia was associated with increased risk of death for older patients with advanced colon cancer; however, some of the effects of dementia on survival could be mediated by receipt of chemotherapy, according to results of a study published by Chen et al in Cancer...
Olaparib Receives Positive pCODR Recommendation for Treatment of BRCA-Mutated Ovarian Cancer
The pan-Canadian Oncology Drug Review (pCODR) has provided a positive clinical recommendation for the reimbursement of olaparib (Lynparza), a first-of-its-kind treatment for BRCA-mutated ovarian cancer. Lynparza is an oral, potent inhibitor of poly (ADP-ribose) polymerase (PARP) available as a...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Benin
The ASCO Post is pleased to continue this special feature on the worldwide cancer burden. Each installment focuses on a country from one of the six regions of the world, as defined by the World Health Organization (ie, Africa, the Americas, South-East Asia, Europe, Eastern Mediterranean, and...
Adjuvant Nivolumab vs Ipilimumab in Resected Stage III or IV Melanoma
The phase III Checkmate 238 trial has shown improved recurrence-free survival with adjuvant nivolumab (Opdivo) vs ipilimumab (Yervoy) in patients with resected advanced melanoma. The findings were reported by Weber and colleagues in The New England Journal of Medicine. Study Details In the...
Durvalumab Consolidation After Chemoradiotherapy in Stage III NSCLC
As reported by Antonia et al in The New England Journal of Medicine, an interim analysis of the phase III PACIFIC trial showed improved progression-free survival with the programmed cell death protein 1 (PD-1) inhibitor durvalumab (Imfinzi) vs placebo as consolidation in patients with unresectable...
How a Child With Cancer Moved From Vulnerability to Resilience
At the time this article was published in the Journal of Clinical Oncology, Dr. Danaher was practicing at Monash -University, -Melbourne, Australia; Drs. Brand and Mack, at Dana-Farber Cancer Institute, Boston; Dr. Pickard, at the Imperial College -Healthcare NHS Trust, London; and Dr. Berry,...
Overdiagnosis of Those in Higher Income Brackets
According to researchers from the Dartmouth Institute for Health Policy and Clinical Practice, being in a high-income bracket may lead to overdiagnosis of cancer and the subsequent harms associated with unnecessary medical treatments. To shed light on this interesting finding and its broader...
Fox Chase Cancer Center Announces New Faculty, Appointments
Under the direction of Martin J. Edelman, MD, Chair, Department of Hematology/Oncology, who joined Fox Chase Cancer Center earlier this year, the department has been reorganized into four sections: Hematologic Malignancies, Solid Tumor Oncology, General Hematology/Oncology, and Fox Chase at Temple...
Douglas R. Lowy, MD, and John T. Schiller, PhD, Receive 2017 Lasker Award
Two scientists at the National Cancer Institute (NCI) received the 2017 Lasker-DeBakey Clinical Medical Research Award for their significant research leading to the development of human papillomavirus (HPV) vaccines. The award is the country’s most prestigious biomedical research prize and was...
Survivorship Resources for Providers and Patients
ASCO OFFERS a bundled resource that combines provider and patient information about cancer survivorship. Providing High Quality Survivorship Care in Practice: An ASCO Guide aims to assist oncologists and other clinicians with implementing high-quality survivorship care programs within their...
ANCO Supports Young Investigator Award for a Northern California Researcher
The Association of Northern California Oncologists (ANCO), an ASCO Affiliate, is among the newest nonprofit supporters of the Conquer Cancer Foundation of the American Society of Clinical Oncology (CCF). ANCO is generously funding a 2018 Young Investigator Award (YIA) for a qualified northern...
Are You Ready for October 2? Plan Ahead for Key QPP Deadline
AS PRACTICES across the country implement the Quality Payment Program (QPP), it’s important to remember that 2017 is a transition year. Practices only have to report one measure for one patient (including at least one Medicare patient) in order to receive a neutral payment adjustment and avoid...
Talking About Physician Burnout: Practical Strategies for Starting the Conversation
Would you rather explain the benefits of three cycles of bleomycin, etoposide, and cisplatin to a hostile crowd of bored teenagers than talk to your program director, supervisor, or colleagues about feeling burned out? It is an understandable feeling. Professional burnout is a difficult concept to...
Original Report in JCO CCI Describes How Authors Developed a Process to Automate a QOPI Measure
A NEW ARTICLE published in JCO Clinical Cancer Informatics (JCO CCI), “Automating QOPI Quality Measure NHL78a,” by Richard P. Mansour, MD, and Samip Master, MD, reports how the authors were able to use data from an electronic health record (EHR) and Microsoft SQL Server database management system...
#WECONQUERCANCER
JOIN THE Conquer Cancer Foundation community of supporters to start a personal fundraising campaign and help create a world free from the fear of cancer. What will you do to help conquer cancer? Honor/remember a loved one Celebrate a special occasion Participate in an endurance event Start...
Clinical Practice Committee, State Affiliate Council Support Innovative Clinical Research—And So Can You
ASCO’s Clinical Practice Committee (CPC) and State Affiliate Council (SAC) have a history of supporting the Conquer Cancer Foundation of ASCO (CCF) Young Investigator Award (YIA) program. Individual members of the CPC and SAC, as well as ASCO State Affiliates, contribute funds to this philanthropic ...
Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
On August 30, 2017, tisagenlecleucel (Kymriah) was granted regular approval for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.1,2 Tisagenlecleucel is the first chimeric antigen receptor (CAR)...
AMA Applauds Surgeon General Nominee
DAVID O. BARBE, MD, President of the American Medical Association (AMA), issued the following statement: "The American Medical Association strongly supports the nomination of Jerome Adams, MD, to become the next Surgeon General of the United States. As Indiana State Health Commissioner, Dr. Adams ...
Gary Kohanbash, PhD, Receives Grant From St. Baldrick’s Foundation
GARY KOHANBASH, PhD, a neuro-oncology researcher at the Children’s Hospital of Pittsburgh of the University of Pittsburgh Medical Center, has been awarded a scholar grant of $298,000 from the St. Baldrick’s Foundation, a volunteer-driven charity dedicated to raising money for childhood cancer...
